Paeds SAQs · neurology-neurodisability-and-neuromuscular
Antiseizure medicines: selection, adverse effects and monitoring — formative SAQs
Formative SAQs on antiseizure medicine selection, adverse effects and monitoring: classifying the drug by spectrum and enzyme effect, choosing the syndrome-matched first-choice medicine, recognising the adverse-effect signature of each agent, applying the valproate pregnancy prevention programme, and managing the lamotrigine rash scenario.
On this page & tools
Target exams
SAQ 1 (10)
A ten-year-old boy with newly diagnosed focal epilepsy is started on levetiracetam. Two weeks later his parents report that he has become increasingly irritable and aggressive, with two episodes of hitting a classmate, which is unlike his baseline. His seizures are controlled. [5] [1]
a) Name the adverse effect, estimate its approximate frequency in children on this drug, and explain why this drug has a favourable interaction profile despite this behavioural effect. (3 marks) [5]
b) Outline three management options for this adverse effect, and state the principle that governs the choice between them. (3 marks) [5]
c) The family asks whether carbamazepine, used by an uncle with epilepsy, might be a better choice. State the spectrum classification of carbamazepine and explain why it is or is not appropriate for this child. (2 marks) [1]
d) Describe the baseline and follow-up monitoring you would arrange for a child on this drug, and explain why routine therapeutic drug monitoring is not required. (2 marks) [5]
SAQ 2 (10)
A fourteen-year-old girl with juvenile myoclonic epilepsy has morning myoclonic jerks and occasional generalised tonic-clonic seizures. Her neurologist has recommended valproate as the most effective single drug. She is sexually active and uses no contraception. [7] [5]
a) State the valproate pregnancy prevention programme, naming the conditions that must be met before valproate is prescribed in a girl of childbearing potential. (3 marks) [7]
b) Name two broad-spectrum alternatives to valproate for this patient and state the principle that governs the choice. (3 marks) [5] [7]
c) If lamotrigine is chosen, state the titration rule and explain why concurrent valproate would require an even slower titration. Name the severe cutaneous adverse effect the slow titration prevents. (2 marks) [11]
d) Describe the transition planning required as she moves to adult care, addressing the medicine review, contraception and pregnancy planning. (2 marks) [7]
References
- [1]Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2013.PMID 23350722
- [5]Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol, 2012.PMID 22832500
- [7]Pack AM, Oskoui M, Williams Roberson S, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology, 2024.PMID 38748979
- [11]Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia, 1999.PMID 10403224